Lv4
710 积分 2021-07-11 加入
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
27天前
已完结
Integrating spatial gene expression and breast tumour morphology via deep learning
1个月前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
1个月前
已完结
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
2个月前
已完结
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
2个月前
已完结
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
2个月前
已完结
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
3个月前
已完结
Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
4个月前
已完结
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 “DICIPLE” Phase III trial
6个月前
已关闭
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration
6个月前
已完结
皖公网安备34019202002308
